A novel local anti-colorectal cancer drug delivery system: Negative lipidoid nanoparticles with a passive target via a size-dependent pattern

Nanotechnology

Volumn 24, Issue 37, 2013, Pages

  Ding, Weifeng ^a   Wang, Feng ^a   Zhang, Jianfeng ^a   Guo, Yibing ^a   Ju, Shaoqing ^a   Wang, Huimin ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-COLORECTAL CANCER DRUGS; CLINICAL DEVELOPMENT; ENDOCYTOTIC PATHWAY; IMMUNE STIMULATION; IN-VIVO EXPERIMENTS; INFLAMMATORY RESPONSE; LOW CYTOTOXICITIES; TRANSFECTION AGENTS;

BIOCOMPATIBILITY; BIOMOLECULES; DISEASES; DRUG DELIVERY; NUCLEIC ACIDS;

NANOPARTICLES;

ANTINEOPLASTIC AGENT; APRIL PROTEIN; LIPID; NANOPARTICLE; SMALL INTERFERING RNA; TNFSF13 PROTEIN, MOUSE;

ANIMAL; ARTICLE; CHEMISTRY; COLORECTAL TUMOR; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; INTESTINE; KIDNEY; LIVER; METABOLISM; MOUSE; PARTICLE SIZE; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; INTESTINES; KIDNEY; LIPIDS; LIVER; MICE; NANOPARTICLES; PARTICLE SIZE; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84883166957     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/24/37/375101     Document Type: Article

References (35)

1. de Fougerolles A, Vornlocher H P, Maraganore J and Lieberman J 2007 Interfering with disease: a progress report on siRNA-based therapeutics Nature Rev. Drug Discov. 6 443-53 (Pubitemid 47064567)
2. McNamara J O II et al 2006 Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras Nature Biotechnol. 24 1005-15 (Pubitemid 44215395)
3. Palliser D, Chowdhury D, Wang Q Y, Lee S J, Bronson R T, Knipe D M and Lieberman J 2006 An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection Nature 439 89-94 (Pubitemid 43053634)
4. Zimmermann T S et al 2006 RNAi-mediated gene silencing in non-human primates Nature 441 111-4
5. Heidel J D et al 2007 Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA Proc. Natl Acad. Sci. USA 104 5715-21 (Pubitemid 47175600)
6. Akinc A et al 2008 A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Nature Biotechnol. 26 561-9 (Pubitemid 351668042)
7. Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A and Chen P 2013 Biocompatibility of engineered nanoparticles for drug delivery J. Control Release 166 182-94
8. Labas R, Beilvert F, Barteau B, David S, Chèvre R and Pitard B 2010 Nature as a source of inspiration for cationic lipid synthesis Genetica 138 153-68
9. Rao N M 2010 Cationic lipid-mediated nucleic acid delivery: beyond being cationic Chem. Phys. Lipids 163 245-52
10. Williams D F 2008 On the mechanisms of biocompatibility Biomaterials 29 2941-53
11. Tan Y, Li S, Pitt B R and Huang L 1999 The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo Hum. Gene Ther. 10 2153-61 (Pubitemid 29416295)
12. Halligan S et al 2013 Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial Lancet 381 1185-93
13. Hahne M et al 1998 APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth J. Exp. Med. 188 1185-90 (Pubitemid 28443341)
14. Ding W et al 2009 APRIL knockdown suppresses migration and invasion of human colon carcinoma cells Clin. Biochem. 42 1694-8
15. Akinc A et al 2009 Development of lipidoid-siRNA formulations for systemic delivery to the liver Mol. Ther. 17 872-9
16. Payne C K, Jones S A, Chen C and Zhuang X 2007 Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands Traffic 8 389-401 (Pubitemid 46421621)
17. Veldhoen S, Laufer S D, Trampe A and Restle T 2006 Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect Nucleic Acids Res. 34 6561-73 (Pubitemid 46017951)
18. Meade B R and Dowdy S F 2008 Enhancing the cellular uptake of siRNAduplexes following noncovalent packaging with protein transduction domain peptides Adv. Drug. Deliv. Rev. 60 530-6
19. Hopkins C R and Trowbridge I S 1983 Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells J. Cell Biol. 97 508-21 (Pubitemid 13041016)
20. Fuchs S M and Raines R T 2004 Pathway for polyarginine entry into mammalian cells Biochemistry 43 2438-44 (Pubitemid 38327839)
21. Baeuerle P A and Huttner W B 1986 Chlorate: a potent inhibitor of protein sulfation in intact cells Biochem. Biophys. Res. Commun. 141 870-7 (Pubitemid 17001937)
22. Kaminskas L M et al 2012 Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models Mol. Pharm. 9 422-32
23. Fenske D B and Cullis P R 2008 Liposomal nanomedicines Expert Opin. Drug Deliv. 5 25-44 (Pubitemid 351234108)
24. Elbert D L and Hubbell J A 1996 Surface treatments of polymers for biocompatibility Annu. Rev. Mater. Sci. 26 365-94 (Pubitemid 126638470)
25. Dobrovolskaia M A and McNeil S E 2007 Immunological properties of engineered nanomaterials Nature Nanotechnol. 2 469-78 (Pubitemid 47220069)
26. Diwan M, Elamanchili P, Cao M and Samuel J 2004 Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery Curr. Drug Deliv. 1 405-12
27. Bermejo J F et al 2007 Water-soluble arbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications Chemistry 13 483-95 (Pubitemid 46104695)
28. Nakanishi T et al 1999 Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins J. Control Release 61 233-40 (Pubitemid 29406095)
29. Sarin H et al 2009 Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors J. Transl. Med. 7 51
30. Milici A J, L'Hernault N and Palade G E 1985 Surface densities of diaphragmed fenestrae and transendothelial channels in different murine capillary beds Circ. Res. 56 709-17 (Pubitemid 15093383)
31. Chang Y et al 2011 In vitro toxicity evaluation of graphene oxide on A549 cells Toxicol. Lett. 200 201-10
32. Dobrovolskaia M A, Aggarwal P, Hall J B and McNeil S E 2008 Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution Mol. Pharm. 5 487-95
33. Howard K A et al 2006 RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system Mol. Ther. 14 476-84 (Pubitemid 44296092)
34. Kim W J, Christensen L V, Jo S, Yockman J W, Jeong J H, Kim Y H and Kim S W 2006 Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma Mol. Ther. 14 343-50 (Pubitemid 44184964)
35. Takahashi N, Tamagawa K, Shimizu K, Fukui T and Maitani Y 2003 Effects on M5076-hepatic metastasis of retinoic acid and N-(4-hydroxyphenyl) retinamide, fenretinide entrapped in SG-liposomes Biol. Pharm. Bull. 26 1060-3 (Pubitemid 41685443)